F. No. IND/FORM44/FF/2019/13238
CDSCO F. No. IND/CT/19/000010
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
New Drugs Division

FDA Bhawan,
Kotla Road, New Delhi
Dated: 08/04/2019

To

M/s Torrent Pharmaceuticals Limited,
Research Centre,
Village Bhat - 382 428,
Dist. Gandhinagar, Gujarat,
India.

Subject: Permission for conducting clinical study entitled, "A Phase II randomized, double blind, placebo controlled, parallel group, multi-centre study to evaluate the efficacy, safety and tolerability of TRC160334 as an add-on to Mesalamine in subjects with Mild to Moderately Active Ulcerative Colitis"- regarding.

CT NOC No.: CT/ND/35/2019

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigator and as per the **Protocol No: CT/P016/IBD/17/02_01, Version No: 1.0, Dated 09.01.2019** submitted to this Directorate.

S. No	Investigator and Trial site	Ethics Committee Name and Registration Number
01	**Dr Mukesh Kalla,** SR Kalla Memorial Gastro & General Hospital, 78-79, Dhuleshwar Garden, S P Marg, Behind HSBC Bank, Sardar Patel Marg, C-Scheme, Jaipur, Rajasthan 302001.	Ethics Committee, SR Kalla Memorial Gastro & General Hospital, 78-79, Dhuleshwar Garden, S P Marg, Behind HSBC Bank, Sardar Patel Marg, C-Scheme, Jaipur, Rajasthan 302001 **ECR/8/Inst/Raj/2013/RR-16**
02	**Dr Amit Agrawal,** Central India Institute of Hematology and Oncology (CIIHO), Plot No. 14/2, Park Corner, Balraj Marg, Near Lokmat Square, Dhantoli, Nagpur-440012, Maharashtra- India	Ethics Committee, Central India Institute of Hematology and Oncology (CIIHO), Plot No. 14/2, Park Corner, Balraj Marg, Near Lokmat Square, Dhantoli, Nagpur-440012, Maharashtra- India **ECR/1079/Inst/MH/2018**
03	**Dr Mukewar Shrikant,** Midas Multispeciality Hospital Pvt Ltd, Midas Heights, 07, Central Bazar Road, Ramdaspeth, Nagpur – 440010	Institutional Ethics Committee, Midas Multispeciality Hospital Pvt. Ltd., Midas Heights, 07, Central Bazar Road, Ramdaspeth, Nagpur – 440010 **ECR/494/Inst/MH/2014/RR-17**

04	**Dr Nitin Pai,** Noble Hospital Pvt Ltd, Corporate Health Check-Up Department, 1st Floor, 153, Magarpatta City Road, Hadapsar, Pune – 411013, Maharashtra- India	Institutional Ethics Committee, Noble Hospital Pvt Ltd, 153, Magarpatta City Road, Hadapsar, Pune – 411013, Maharashtra- India **ECR/259/Inst/MH/2013/RR-16**
05	**Dr. Ravishankar Reddy,** Aware Gleneagles Global Hospitals, 08-16-01, Near Sagar X Road, Saroornagar, L. B. Nagar, Hyderabad-500035, Telangana.	Ethics Committee, Gleneagles Global Hospital, A Unit of Ravindranath GE Medical Associates Pvt. Ltd., 6-1-1070/1 to 4, Lakdikapul, Hyderabad-500004, Telangana, **ECR/158/Inst/AP/2013/RR-16**
06	**Dr. Kabrawala Mayank,** Surat Institute of Digestive Science, Vijaynagar Gate No. 3, Besides Nirma Bhavan, Oppo. Gandhi Collage, Majura Gate, Ring Road, Surat 395002, Gujarat , India	Ethics Committee, Surat Institute of Digestive Science, Vijaynagar Gate No. 3, Besides Nirma Bhavan, Oppo. Gandhi Collage, Majura Gate, Ring Road, Surat 395002, Gujarat , India **ECR/813/Inst/GJ/2016**

Kindly note that the clinical trial permission is subject to the following conditions:-

a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.

b) Approval of Institutional Ethics Committee duly registered with CDSCO (under Rule 122DD of Drugs & Cosmetics Rules) should be obtained and submitted to this Directorate before initiation of the study.

c) Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.

d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.

e) Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.

f) In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.

g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.

h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

i) Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

j) The sponsor shall ensure that the number of clinical trials an investigator can undertake should be commensurate with the nature of the trial, facility available with the Investigator etc.

k) The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.

l) In addition to the requirement of obtaining written informed consent, an audio-video recording of the informed consent process in case of vulnerable subjects in clinical trial of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record; provided that in case of clinical trial of anti-HIV and anti-leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record, as per Government of India, Gazette Notification vide G. S. R. no. 611(E) dated 31.07.2015.

m) Investigational products shall be manufactured under GMP conditions using validated procedures and shall have ongoing stability programme.

n) If the clinical trial batches are different from that of the primary batches for which data have been submitted, stability reports for clinical trial batches are to be submitted as per Appendix IX of schedule Y of drugs and Cosmetics Rules for Drug substances and formulation along with Clinical study Report.

o) It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

p) Informed consent documents (ICD) viz. Patient Information sheet (PIS) and Informed Consent form (ICF) complete in all respect as per the requirements specified in Appendix V of Schedule Y of the Drugs and cosmetics Rules, 1945 must got approved from the respective Ethics Committee and Submitted to CDSCO before enrolling first subject at the respective site.

q) The IND committee held on 15.03.2019, recommended for grant of permission to conduct the clinical trial subject to following conditions:-

1. The inclusion criteria "Subjects on stable dose of oral mesalamine of at least 2.4 gm/day for 2 weeks prior to screening" should be revised to - "Subjects on stable dose of oral mesalamine at 2.4 gm/day or higher recommended dose as tolerated for 2 weeks prior to screening".
2. The haematological analysis of the patients should also include the assessment of Erythropoetin at 4, 12 and 13 weeks of the study.
3. Biochemical and Urine analysis of the patients should be done at 2, 4, 12 and 13 weeks of the study.

The firm shall submit the revised clinical trial protocol to CDSCO before initiation of clinical trial.

Yours faithfully,

(Dr. S. Eswara Reddy)
Drugs Controller General (India)
and Licensing Authority